Alaunos Therapeutics, Inc.
TCRT
$2.63
-$0.05-1.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 300.00% | -- | 0.00% | -- | -90.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 300.00% | -- | 0.00% | -- | -90.91% |
| Cost of Revenue | -109.22% | -96.09% | -96.53% | -98.06% | -69.97% |
| Gross Profit | 109.66% | 96.09% | 96.60% | 98.08% | 69.90% |
| SG&A Expenses | -65.20% | -71.86% | -67.49% | -48.96% | -16.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -77.42% | -84.10% | -85.79% | -81.98% | -44.28% |
| Operating Income | 77.53% | 84.10% | 85.83% | 81.99% | 44.20% |
| Income Before Tax | 90.54% | 86.70% | 87.13% | 83.26% | 14.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.54% | 86.70% | 87.13% | 83.26% | 14.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.54% | 86.70% | 87.13% | 83.26% | 14.37% |
| EBIT | 77.53% | 84.10% | 85.83% | 81.99% | 44.20% |
| EBITDA | 75.81% | 82.46% | 84.52% | 80.61% | 41.45% |
| EPS Basic | 90.54% | 86.71% | 87.15% | 83.30% | 20.35% |
| Normalized Basic EPS | 77.20% | 84.01% | 87.50% | 83.30% | 54.55% |
| EPS Diluted | 90.54% | 86.71% | 87.15% | 83.30% | 25.78% |
| Normalized Diluted EPS | 77.20% | 84.01% | 87.50% | 83.30% | 54.55% |
| Average Basic Shares Outstanding | 0.00% | 0.06% | 0.16% | 0.21% | 7.51% |
| Average Diluted Shares Outstanding | 0.00% | 0.06% | 0.16% | 0.21% | 7.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |